

Highlights

The Action's 3rd Grant Period (GP) finalized by the end of April 2016. We have just started the 4th GP! We will inform you about the activities programed within this new GP in due course. Keep an eye on our website for further updates. Find below a summary of the last activities celebrated within the 3rd GP:

WG1 & WG4: The PancreOS (Pancreatic Cancer Overall Survival Registry) kick-off meeting took place on 17th March 2016 at CNIO (Madrid, Spain). Chairs: Alfredo Carrato and Núria Malats. Representatives from over 8 European countries attended the meeting along with representatives of different initiatives and supporting organizations (JCR/ENCR, EUROCARE, BACAP, HPSG, PCE, Celgene, etc.). In brief, discussions were held around the results of the pilot study, definition of variables and the next steps to be taken to implement the PancreOS registry. Minutes of the meeting and presentations can be downloaded from eupancreas.com/wg4

WG2: Training School on Interactions in Complex Disease Analysis. April 27-29, Antwerp (Belgium). Chair: Kristel Van Steen. The school covered the different scenarios of data analysis where interaction needs to be assessed, including statistical versus biological interactions, gene-gene and gene-environment interactions, causality, dynamical interaction systems, symbiotic and pathogenic interactions, protein networks and components-based path modeling. The COST Action supported 14 EUPancreas trainees and 2 trainers. Presentations are available at eupancreas.com/training

WG3: Members of WG3 set up a project on pancreatic cancer (WG3 work stream on diabetes) that was submitted to a recent H2020 call. We wish them every success!

WG4: IV Annual EAPM Conference on personalized medicine. April 5-7, Brussel (Belgium). Stakeholder groups, healthcare professionals, academics, industry representatives, politicians and legislators, discussed around the theme "Taking Stock: Where we are now and the necessary next steps to take to realize an environment for personalised medicine." Several EUPancreas members attended this meeting.

The World Pancreatic Coalition will be launched in May 2016 during the AACR conference. Ali Stunt will be the Co-Chair of the inaugural meeting. Updated information will be published at eupancreas.com

The EUPancreas platform joins at present **245 European pancreatic cancer researchers**.

Twitter: @Pancreas has now 137 followers!

Forthcoming event

WG3: Training School on "Genomic Medicine". May 3-7, Portoroz (Slovenia). Chair: Vita Dolzan. Everything is ready for this upcoming event. The COST Action will support the attendance of 4 EUPancreas trainees and 2 trainers. Topics cover epidemiology, pathogenesis/pathology, and treatment modalities for pancreas cancer. In addition, a satellite workshop "In vitro and in vivo models for development of novel diagnostic and therapeutic approaches" will be held. Have a look at the abstract book at eupancreas.com/training

Early Career Investigators (ECIs):

- ❖ EAPM Summer School on Personalised Medicine. Further information is available at eupancreas.com
- ❖ Travel grants to attend the European Pancreatic Club (EPC) are available for young investigators. See eligibility criteria at the meeting's website.

Upcoming Scientific Events:

- ❑ **9 to 12 June:** International Symposium on Pancreatic Cancer 2016. Glasgow, UK
- ❑ **29 June to 2 July:** ESMO World Congress on Gastrointestinal cancer. Barcelona, Spain
- ❑ **11 to 15 May:** AACR Pancreatic Cancer Special Conference. Orlando, USA

EUPancreas members will be participating in two new events.

Information will be provided shortly at eupancreas.com

- ❑ **22 to 23 June:** Panc4 (Pancreatic Cancer case-control consortium) meeting. Milan, Italy
- ❑ **6 to 9 July:** 48th meeting of the European Pancreatic Club (EPC). Liverpool, UK
- ❑ **17 to 18 November:** HBP SurG Meeting 2016. Lyon, France.



The World of Interactions Around Us



New pancreatic cancer-related studies:

Publications acknowledging the "COST Action BM1204 EU-Pancreas"

📄 Benitz, et al. Polycomb repressor complex 1 promotes gene silencing through H2AK119 mono-ubiquitination in acinar-to-ductal metaplasia and pancreatic cancer cells. *Oncotarget*. 2016;7(10):11424-33.

Other publications:

📄 Vasen, et al. Benefit of Surveillance for Pancreatic Cancer in High-Risk Individuals: Outcome of Long-Term Prospective Follow-Up Studies From Three European Expert Centers. *J Clin Oncol* April 2016 [Epub ahead of print]

📄 Jorgensen, et al. Is screening for pancreatic cancer in high-risk groups cost-effective? - Experience from a Danish national screening program. *Pancreatology* March 2016 [Epub ahead of print]

📄 Frampton, et al. Prospective validation of microRNA signatures for detecting pancreatic malignant transformation in endoscopic-ultrasound guided fine-needle aspiration biopsies. *Oncotarget* April 2016 [Epub ahead of print]